Compare ACR & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACR | SGMT |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.1M | 169.4M |
| IPO Year | N/A | 2021 |
| Metric | ACR | SGMT |
|---|---|---|
| Price | $18.50 | $7.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $24.50 | ★ $26.13 |
| AVG Volume (30 Days) | 40.5K | ★ 781.4K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.61 | $4.50 |
| 52 Week High | $24.61 | $11.41 |
| Indicator | ACR | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 47.92 | 55.64 |
| Support Level | $17.56 | $6.26 |
| Resistance Level | $19.47 | $7.20 |
| Average True Range (ATR) | 0.84 | 0.33 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 75.96 | 76.82 |
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding, and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralized debt obligations, and private equity investments mainly issued by financial institutions.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.